170 related articles for article (PubMed ID: 31601999)
1. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Geist MJP; Ziesenitz VC; Bardenheuer HJ; Burhenne J; Skopp G; Mikus G
Sci Rep; 2019 Oct; 9(1):14635. PubMed ID: 31601999
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole.
Ziesenitz VC; König SK; Mahlke NS; Skopp G; Haefeli WE; Mikus G
J Clin Pharmacol; 2015 Jun; 55(6):708-17. PubMed ID: 25651378
[TBL] [Abstract][Full Text] [Related]
3. Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies.
Geist MJP; Siller N; Egerer G; Bardenheuer H; Burhenne J; Mikus G
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):117-122. PubMed ID: 30916851
[TBL] [Abstract][Full Text] [Related]
4. Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A.
Geist M; Bardenheuer H; Burhenne J; Mikus G
Palliat Med; 2019 Jul; 33(7):850-855. PubMed ID: 31023150
[TBL] [Abstract][Full Text] [Related]
5. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Kharasch ED; Whittington D; Hoffer C
Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period.
Tanaka N; Naito T; Yagi T; Doi M; Sato S; Kawakami J
Ther Drug Monit; 2014 Jun; 36(3):345-52. PubMed ID: 24365989
[TBL] [Abstract][Full Text] [Related]
7. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Barratt DT; Bandak B; Klepstad P; Dale O; Kaasa S; Christrup LL; Tuke J; Somogyi AA
Pharmacogenet Genomics; 2014 Apr; 24(4):185-94. PubMed ID: 24469018
[TBL] [Abstract][Full Text] [Related]
8. Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Bista SR; Haywood A; Hardy J; Norris R; Hennig S
J Clin Pharmacol; 2016 Jun; 56(6):705-13. PubMed ID: 26381285
[TBL] [Abstract][Full Text] [Related]
9. Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.
Van Nimmen NF; Poels KL; Menten JJ; Godderis L; Veulemans HA
J Clin Pharmacol; 2010 Jun; 50(6):667-78. PubMed ID: 20097932
[TBL] [Abstract][Full Text] [Related]
10. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Oosten AW; Abrantes JA; Jönsson S; de Bruijn P; Kuip EJ; Falcão A; van der Rijt CC; Mathijssen RH
Eur J Clin Pharmacol; 2016 Apr; 72(4):459-67. PubMed ID: 26762381
[TBL] [Abstract][Full Text] [Related]
11. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.
Empey PE; Miller TM; Philbrick AH; Melick JA; Kochanek PM; Poloyac SM
Crit Care Med; 2012 Apr; 40(4):1221-8. PubMed ID: 22067624
[TBL] [Abstract][Full Text] [Related]
12. LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems.
Coopman V; Cordonnier J; Pien K; Van Varenbergh D
Forensic Sci Int; 2007 Jul; 169(2-3):223-7. PubMed ID: 16650707
[TBL] [Abstract][Full Text] [Related]
13. Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer.
Bista SR; Haywood A; Norris R; Good P; Tapuni A; Lobb M; Hardy J
Clin Ther; 2015 Nov; 37(11):2468-75. PubMed ID: 26404396
[TBL] [Abstract][Full Text] [Related]
14. In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial.
Geist MJP; Bardenheuer HJ; Burhenne J; Mikus G
J Palliat Med; 2018 May; 21(5):686-688. PubMed ID: 29327978
[TBL] [Abstract][Full Text] [Related]
15. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Labroo RB; Paine MF; Thummel KE; Kharasch ED
Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation.
Smith JS; Coetzee JF; Fisher IWG; Borts DJ; Mochel JP
J Vet Pharmacol Ther; 2018 Aug; 41(4):555-561. PubMed ID: 29603262
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
18. Fast increase of postmortem fentanyl blood concentrations after transdermal application: A call to careful interpretation.
Reiter A; Mueller A; Otto B; Anders S; Falckenberg M; Iwersen-Bergmann S; Andresen-Streichert H
Forensic Sci Int; 2019 Sep; 302():109896. PubMed ID: 31426021
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
Kokubun H; Ebinuma K; Matoba M; Takayanagi R; Yamada Y; Yago K
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):98-104. PubMed ID: 22764844
[TBL] [Abstract][Full Text] [Related]
20. Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.
Kuip EJM; Oldenmenger WH; Thijs-Visser MF; de Bruijn P; Oosten AW; Oomen-de Hoop E; Koolen SLW; Van der Rijt CCD; Mathijssen RHJ
PLoS One; 2018; 13(6):e0198289. PubMed ID: 29883454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
